openPR Logo
Press release

Porphyrias Treatment Market:Growth Dynamics| by Key Vendors - H. Lundbeck A/S, Recordati Rare Diseases Inc., Teva Pharmaceutical Industries Ltd.

06-03-2019 02:45 PM CET | Health & Medicine

Press release from: Future Market Insights

Porphyrias Treatment Market:Growth Dynamics| by Key Vendors -

Porphyrias is a rare genetic disorder which can cause skin or nerve problems. Porphyria that affects the nervous system is known as acute porphyria whereas which affects the skin is termed as cutaneous porphyria. There are various types of porphyria which are generally classified into two categories: erythropoietic and hepatic. Erythropoietic forms are caused by problems in RBCs whereas hepatic forms of the disorder are caused by problems in the liver. Each different type of porphyria signifies a deficiency of a specific enzyme required for the synthesis of heme. Porphyrias treatment is specific to the type of porphyria. Based on the type of porphyrias different test are performed for the diagnosis purpose. Tests include a combination of blood, urine or stool testing. Porphyria has many signs and symptoms ranging from mild to severe which are very similar to other common diseases. Some of the common symptoms of porphyria are light sensitivity (causing blisters or rashes), abdominal pain, and problems with the nervous system. Porphyrias treatment may include avoiding the triggers, taking medicines to relieve symptoms, receiving heme through a vein, or having blood drawn to reduce iron in the body. Presently, there is no cure for porphyria but there are porphyrias treatment available based on the type of disease.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8917

Porphyrias Treatment Market: Key Players

Examples of some of the key players in the global porphyrias treatment market are H. Lundbeck A/S, Recordati Rare Diseases Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Allergan plc, Apotex Inc., Pfizer Inc., and others.

Panhematin is the only commercially available heme therapy in the U.S. for porphyrias treatment. People with severe porphyric attacks are treated with heme given by vein. If porphyrias treatment is delayed, then recovery takes longer and some nerve damage may be permanent. Furthermore, a high carbohydrate diet and intravenous glucose therapy for mild attacks are usually recommended for porphyrias treatment. Liver transplantation is recommended for acute intermittent porphyria.

Porphyrias Treatment Market: Drivers and Restraints

It is observed that the continuous rise in research grants and R&D expenditures from government and other pharma companies in order to fuel the development of rare disease drugs which would change the landscape of porphyrias treatment over the forecast period of 2018–2028. Thus the development of drugs for porphyrias treatment by leading biotechnology companies is becoming one of the prominent drivers in driving the growth of the global porphyrias treatment market. Unlike other pharmaceutical drugs, less competition in the porphyrias treatment market encourages the entry of new drug makers to invest in the research and development for porphyrias treatment. However, the prevalence of porphyria is still unknown but according to clinicians a range of 1 per 500-50,000 of the population is expected. The high treatment cost and challenges to reimbursement for porphyrias treatment are the factors limiting the growth of global porphyrias treatment market.

Porphyrias Treatment Market: Segmentation

The global porphyrias treatment market is segmented by drug class, route of administration, distribution channel and region:

Based on the drug class, the global porphyrias treatment market is segmented into:

Porphyrin (Panhematin)

Dextrose

Anticonvulsants

Opioids

Others

Based on the route of administration, the global porphyrias treatment market is segmented into:

Oral

Injectable

Based on the distribution channel, the global porphyrias treatment market is segmented into:

Hospital Pharmacies

Retail Pharmacies

e-commerce

Others

Porphyrias Treatment Market: Overview

Porphyria is a disorder which is hard to diagnose and requires blood, urine and stool tests. Porphyrias treatment for acute attacks requires to decrease heme synthesis and reduce the production of porphyrin precursors. An approved orphan drug earlier known as hemin, now called panhematin, is used as a treatment for various types of porphyria. The global porphyrias treatment market is expected to grow at a significant growth rate over the forecast period. Based on the distribution channel, the global porphyrias treatment market is segmented into hospital pharmacies, e-commerce, retail pharmacies, and others.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-8917

Porphyrias Treatment Market: Regional Outlook

On the basis of geography, the global porphyrias treatment market is segmented into eight key regions, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China and Japan, China, Japan, and Middle East & Africa. North America is anticipated to hold maximum market share in the global porphyrias treatment market due to the favourable reimbursement policies and presence of key players in the region. Asia Pacific porphyrias treatment market is projected to grow at maximum growth rate over the forecast period. This is majorly due to the entry of new players and rising awareness towards porphyrias treatment. The Middle East & Africa porphyrias treatment market is expected to hold minimum share in the global porphyrias treatment market owing to the lack of clear strategies to access healthcare support for porphyrias treatment.

ABOUT US:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Porphyrias Treatment Market:Growth Dynamics| by Key Vendors - H. Lundbeck A/S, Recordati Rare Diseases Inc., Teva Pharmaceutical Industries Ltd. here

News-ID: 1762690 • Views:

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute

All 5 Releases


More Releases for Porphyria

Porphyria Targeting Therapies Market, 2021-2030
Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings. Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can
Acute Intermittent Porphyria Treatment Market Global Analysis 2020 to 2026 | Abb …
The Acute Intermittent Porphyria Treatment Market 2020 report is a comprehensive, professional and in-depth research of market that delivers significant data for those who are seeking information for the Acute Intermittent Porphyria Treatment industry. The market report delivers the specification, key strategies, future prospect and cost structure of the industry. The report also highlighted the future trends in the Acute Intermittent Porphyria Treatment market that will impact the demand during
Porphyria Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Alny …
Porphyria is a group of disorders including cutaneous porphyria and acute porphyria. Cutaneous porphyria affects the skin while acute porphyria affects the nervous system. Porphyria cutanea tarda is the most common type of porphyria prevalent in the U.S. Download the sample report at: https://www.pharmaproff.com/request-sample/1043 The common symptoms of porphyria are abdominal pain, chest pain, increased blood pressure, increased heart rate, muscle weakness, cramping, blisters, itching, swelling, constipation, vomiting, mental disorders,
Global Swedish Porphyria Industry Assesment report 2018-2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Swedish Porphyria market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base year
Acute Intermittent Porphyria Drugs Market: Global Industry Analysis Report 2018
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Acute Intermittent Porphyria Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from
Acute Intermittent Porphyria Market Growth and Value Chain Analysis 2018 – 202 …
Acute intermittent porphyria (AIP) is a hereditary metabolic disorder. It affects the production of heme, which is the prosthetic group of hemoglobin binding to oxygen. It is caused due to low enzyme porphobilinogen deaminase. The main reasons for acute intermittent porphyria are insomnia, anorexia, and change in coloration of urine, myalgia, and retention of urine. At times, AIP results in the formation of liver tumor (hepatocellular carcinoma) and kidney failure. Request